Premium
Selective Cyclin‐Dependent Kinase Inhibitors Discriminating between Cell Cycle and Transcriptional Kinases
Author(s) -
WęsierskaGądek Józefa,
Kryštof Vladimír
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.04726.x
Subject(s) - cyclin dependent kinase , kinase , cell cycle , cdk inhibitor , microbiology and biotechnology , cyclin dependent kinase 2 , polo like kinase , biology , restriction point , cyclin , cell , biochemistry , protein kinase a
Progression of the cell cycle is controlled by activating and inhibiting cellular factors. The delicate balance between these positive‐ and negative‐acting regulators warrants proper cell cycle progression in normal cells and facilitates cellular response to a variety of stress stimuli. The increased activity of the positive regulators of the cell cycle in cancer cells is frequently accompanied by the loss or inactivation of the inhibitors of cyclin‐dependent kinases (CDKs). The supplementation of the cellular CDK inhibitors by the pharmacological counterparts is a very promising therapeutic option. The generated pharmacological inhibitors of CDKs belong to different classes of compounds and display various CDK inhibitory features. In this article the action and specificity of CDK inhibitor roscovitine, belonging to the group of purine analogues, is reviewed and the rationale for dissecting the inhibitory action on cell cycle and transcriptional CDKs is discussed.